A $100 Billion Opportunity Just Getting Started
from Nanalyze Hosted by Nanalyze
The cure for cancer - at least today - is early detection. That's because if you can detect cancer soon enough, the chance for survival increases dramatically. We've identified two pure-play companies using blood tests for cancer detection, what's known as "liquid biopsy." Those companies are Guardant Health $GH and GRAIL $GRAL. Both offer a "multi-cancer" test, meaning you can screen for multiple cancers with a single blood sample. The market opportunity is measured in the hundreds of billions of dollars. Can these companies succeed where Theranos failed? Stay informed with our free disruptive technology investing newsletter, Nanalyze Weekly. Sign up now at https://www.nanalyze.com/nanalyze-weekly/. This episode is pulled from a YouTube presentation. View the original presentation at https://youtu.be/ARxnaI_L098.
Embed this episode
No transcript yet.